Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study

Yoshikuni Mizuno, Kazuko Hasegawa, Tomoyoshi Kondo, Sadako Kuno, Mitsutoshi Yamamoto, K. Sakou, M. Shoji, T. Abe, H. Nomura, T. Maeda, S. Shintani, A. Tamaoka, K. Hirata, R. Hishida, I. Nakano, K. Okamoto, M. Asahina, H. Shimura, H. Hashida, H. MochizukiH. Mizusawa, R. Hanajima, Y. Suzuki, S. Nakamura, M. Yokochi, F. Yokochi, H. Takahashi, T. Hashimoto, H. Morita, H. Miyajima, T. Ohashi, T. Atsumi, K. Mizoguchi, T. Hattori, H. Sawada, Y. Tatsuoka, S. Matsumoto, H. Fujimura, H. Miwa, K. Nakashima, J. Yoshinaga, M. Nomoto, T. Yamada, T. Uozumi, H. Tanji, A. Takeda, N. Kawashima, Y. Ishigaki

Research output: Contribution to journalArticlepeer-review

143 Citations (Scopus)


The objectives of this study were to evaluate the efficacy of istradefylline at an oral dose of 20 mg or 40 mg once daily for 12 weeks in Parkinson's disease (PD) patients with motor complications on levodopa therapy based on the change in the daily OFF time compared with placebo and to assess the safety at these doses. A total of 363 subjects were randomly assigned to receive 20 mg/day istradefylline (n = 119), 40 mg/day istradefylline (n = 125), or placebo (n = 119). The primary outcome variable was the change from baseline at endpoint in daily OFF time based on patients' ON/OFF diaries. At endpoint, the daily OFF time reduced from baseline by 1.31 hours for 20 mg/day istradefylline (P = 0.013 as compared to the placebo), 1.58 hours for 40 mg/day istradefylline (P < 0.001), and 0.66 hours for placebo; istradefylline significantly reduced the daily OFF time compared with placebo. The UPDRS Part III subscale score (ON state) reduced by 5.7 at endpoint in both istradefylline groups and 3.7 in the placebo group (P = 0.006 for 20 mg/day and P = 0.006 for 40 mg/day group as compared with placebo). The most commonly reported drug-related treatment emergent adverse event (TEAE) was dyskinesia, which occurred in 2.5% (3/119) of subjects receiving placebo, 8.5% (10/118) receiving 20 mg/day istradefylline, and 6.4% (8/125) receiving 40 mg/day istradefylline. We conclude that istradefylline at 20 mg and 40 mg once daily is effective in relieving wearing-off fluctuations of PD patients. In addition, istradefylline was well tolerated at both doses.

Original languageEnglish
Pages (from-to)1437-1443
Number of pages7
JournalMovement Disorders
Issue number10
Publication statusPublished - 2010 Jul 30
Externally publishedYes


  • Adenosine antagonists
  • Istradefylline
  • Levodopa
  • Parkinson's disease
  • Randomized controlled trial

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study'. Together they form a unique fingerprint.

Cite this